

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Potential issues raised in response to consultation on the draft scope are listed below:

- In the UK, endometrial cancer survival outcomes are associated with socio-economic deprivation. Women from the middle and most deprived socio-economic groups were more likely to die from endometrial cancer, with a two-fold and a 53% increased risk respectively, compared with the less deprived women.
- Ethnicity influences endometrial cancer survival outcomes. A study found significant demographic differences between co-located South Asian and White patients with endometrial cancer, including younger age at diagnosis and more premenopausal cases in the South Asian patient group. This suggests potential disparities in cancer referral criteria based on ethnicity.
- Recent ONS data demonstrated significant disparities in endometrial cancer mortality, with Black ethnic groups in the UK experiencing notably higher rates compared with other ethnicities. Diagnosis at late stages appears more frequent among Black Caribbean and Black African women compared with women from other groups.

The approval of dostarlimab with platinum-containing chemotherapy as part of routine commissioning would help to address the severe

Health Technology Evaluation: Scoping

Equality impact assessment for the Health Technology Evaluation of dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]

Issue date: July 2024

1 of 2

inequalities existing in survival outcomes experienced amongst endometrial cancer patients of different ethnicities or experiencing different levels of socio-economic deprivation.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee considered potential equality issues raised during TA963. The committee's considerations are in section 3.16 of the [final guidance for TA963](#). The committee for this topic will reconsider any potential equality issues.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No additional stakeholders related to potential equality issues were identified during the scoping process.

Approved by Associate Director (name): ...Janet Robertson.....

Date: 24/07/24